Stanford
Foresight Diagnostics Commercializing PhasED-seq Liquid Biopsy Tech for Improved MRD Detection
Premium
The technology, developed by researchers at Stanford, showed strong performance in a new study of lymphoma, and early data for solid tumors is already available.
In Brief This Week: Foundation Medicine, Myriad Genetics, Immunovia, Biocept, and More
News items for the in vitro diagnostics industry for the week of June 28, 2021.
Foresight Diagnostics Raises $12.5M in Series A to Commercialize MRD Detection Tech
The company, founded by Stanford University scientists, is advancing a technology called PhasED-Seq for cancer minimal residual disease detection.
Amazon to Give Out $12M Under Next Phase of AWS Diagnostics Development Initiative
The company is planning to fund projects for SARS-CoV-2 testing, early disease detection, disease prognostics, and public health genomics projects.
Fluidigm CEO Chris Linthwaite said the company aims to further penetrate the diagnostic and clinical markets with both its microfluidics and mass cytometry businesses.
Feb 3, 2021
Nov 18, 2019
Nov 1, 2019
Oct 31, 2019